Pregnant patients receiving medication to treat opioid use disorder should not reduce their medication dose out of fear that it will worsen withdrawal symptoms in their newborns, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM).
Study Reassures Pregnant Women on Opioid Use Disorder Treatment
A study from the University of Maryland School of Medicine indicates that pregnant women undergoing treatment for opioid use disorder should maintain their medication dosage to prevent worsening withdrawal symptoms in newborns. This research is crucial as it addresses the health of mothers and infants, which is relevant for Iran's ongoing struggles with opioid addiction. Understanding effective treatment methods can inform healthcare policies in Iran.
👥 Key Players
📰 What Happened
A study found that pregnant women being treated for opioid use disorder should not lower their medication dosage due to concerns about newborn withdrawal symptoms. Maintaining dosage is crucial for the health of both the mother and the baby.
- The study emphasizes the importance of consistent medication for pregnant women with opioid use disorder.
- Reducing medication can lead to worse withdrawal symptoms in newborns.
💡 Why It Matters
📚 Background
Opioid use disorder is a significant public health issue worldwide, and pregnant women are particularly vulnerable due to the risks to both their health and that of their infants.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%